US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fractyl Health

1.61

-0.5300-24.77%

Post-market: 1.680.0700+4.35%18:53 EDT

Volume:6.20M

Turnover:12.88M

Market Cap:78.85M

PE:-0.87

High:1.98

Open:1.75

Low:1.55

Close:2.14

Loading ...

Overview Company News Filings

Fractyl Health Unveils Positive REMAIN-1 Study Results

Fractyl Health Announces Positive 3-Month Data from REVEAL-1 Cohort, Highlighting Revita's Potential for Sustained Weight Loss After GLP-1 Discontinuation

Fractyl Health Inc - Median Weight Remained Stable Through 3 Months

THOMSON REUTERS

Fractyl Health Inc - Revita Shows Excellent Tolerability Profile Compared to Glp-1 Drugs

THOMSON REUTERS

Fractyl Health Reports Positive 3-Month Reveal-1 Cohort Data Showing Revita® Sustained Weight Loss After Glp-1 Discontinuation, Supporting Its Potential as a First-in-Class Weight Maintenance Therapy

THOMSON REUTERS

Fractyl Health Inc - Randomized Midpoint Cohort Data Expected in Q3 2025

THOMSON REUTERS

Fractyl Health Inc. Advances Rejuva Platform with Preclinical Success, Eyes First Human Trials for RJVA-001 in 2026

Fractyl Health Announces New Patents for Gut Therapies

Fractyl Health Expands Intellectual Property Portfolio with Two New U.S. Patents for Metabolic Disease Innovations

Fractyl Health Inc. Unveils Promising Preclinical Data on GLP-1-Based Gene Therapy for Obesity and Diabetes Prevention at ADA Scientific Sessions

Fractyl Health Inc. Conducted Annual Meeting of Stockholders

BRIEF-Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide

Fractyl Health, Bariendo sign non-binding LOI, to offer Revita nationwide

Fractyl Health Inc - Expects Key Data Readouts for Revita in 2025 and 2026

THOMSON REUTERS

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across Its Bariatric and Metabolic Endoscopy Centers Nationwide

THOMSON REUTERS

Fractyl Health and Bariendo Join Forces to Potentially Offer Revita Nationwide for Post-GLP-1 Weight Maintenance

Innovative Weight Management Solution Drives Buy Rating for Fractyl Health

Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001

MT Newswires Live

Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes

Fractyl Health Advances Rejuva® Gene Therapy Platform With Submission of First Clinical Trial Application Module in Europe for Rjva-001 in Type 2 Diabetes

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GUTS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GUTS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GUTS\",,,,,undefined,":{"symbol":"GUTS","market":"US","secType":"STK","nameCN":"Fractyl Health","latestPrice":1.61,"timestamp":1750708800000,"preClose":2.14,"halted":0,"volume":6202035,"hourTrading":{"tag":"盘后","latestPrice":1.68,"preClose":1.61,"latestTime":"18:53 EDT","volume":20782,"amount":33640.5549264,"timestamp":1750719224166},"delay":0,"floatShares":18161148,"shares":48976636,"eps":-1.843961,"marketStatus":"Post-Mkt","change":-0.53,"latestTime":"06-23 19:03:20 EDT","open":1.75,"high":1.98,"low":1.55,"amount":12883539.402594,"amplitude":0.200935,"askPrice":1.99,"askSize":100,"bidPrice":1.61,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.843961,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750723200000},"marketStatusCode":4,"adr":0,"listingDate":1706850000000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":1.77,"preClose":2.14,"latestTime":"09:29 EDT","volume":1841067,"amount":4051484.4429792003,"timestamp":1750685391433},"postHourTrading":{"tag":"盘后","latestPrice":1.68,"preClose":1.61,"latestTime":"18:53 EDT","volume":20782,"amount":33640.5549264,"timestamp":1750719224166},"volumeRatio":24.401052},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GUTS\",,,,,undefined,":{"symbol":"GUTS","floatShares":18161148,"roa":"-49.05%","roe":"-196.81%","lyrEps":-1.617559,"volumeRatio":24.401052,"shares":48976636,"dividePrice":0,"high":1.98,"amplitude":0.200935,"preClose":2.14,"low":1.55,"week52Low":0.873,"pbRate":"12.37","psRate":"1314.21","week52High":5.3432,"institutionHeld":0,"latestPrice":1.61,"eps":-1.843961,"divideRate":0,"volume":6202035,"delay":0,"ttmEps":-1.843961,"open":1.75,"prevYearClose":2.06,"prevWeekClose":2.14,"prevMonthClose":1.9,"prevQuarterClose":1.19,"fiveDayClose":2.06,"twentyDayClose":1.755,"sixtyDayClose":1.27},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GUTS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545446544","title":"Fractyl Health Unveils Positive REMAIN-1 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2545446544","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545446544?lang=en_us&edition=fundamental","pubTime":"2025-06-24 02:39","pubTimestamp":1750703963,"startTime":"0","endTime":"0","summary":"An update from Fractyl Health, Inc. ( ($GUTS) ) is now available. On June 23, 2025, Fractyl Health, Inc. announced positive 3-month data from the R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fractyl-health-unveils-positive-remain-1-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fractyl-health-unveils-positive-remain-1-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GUTS","BK4082"],"gpt_icon":0},{"id":"2545160664","title":"Fractyl Health Announces Positive 3-Month Data from REVEAL-1 Cohort, Highlighting Revita's Potential for Sustained Weight Loss After GLP-1 Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545160664","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545160664?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678829,"startTime":"0","endTime":"0","summary":"Fractyl Health Announces Positive 3-Month Data from REVEAL-1 Cohort, Highlighting Revita's Potential for Sustained Weight Loss After GLP-1 Discontinuation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire  on June 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLMcGYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","GUTS","BK4112","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","BK4082","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2545419886","title":"Fractyl Health Inc - Median Weight Remained Stable Through 3 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419886?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA3H67LF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GUTS","BK4082"],"gpt_icon":0},{"id":"2545419884","title":"Fractyl Health Inc - Revita Shows Excellent Tolerability Profile Compared to Glp-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419884?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA3H67LF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GUTS","BK4082"],"gpt_icon":0},{"id":"2545419883","title":"Fractyl Health Reports Positive 3-Month Reveal-1 Cohort Data Showing Revita® Sustained Weight Loss After Glp-1 Discontinuation, Supporting Its Potential as a First-in-Class Weight Maintenance Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419883?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA3H67LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GUTS","BK4082"],"gpt_icon":0},{"id":"2545198334","title":"Fractyl Health Inc - Randomized Midpoint Cohort Data Expected in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2545198334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545198334?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:40","pubTimestamp":1750678800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA3H67LF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2545470416","title":"Fractyl Health Inc. Advances Rejuva Platform with Preclinical Success, Eyes First Human Trials for RJVA-001 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2545470416","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545470416?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:30","pubTimestamp":1750678228,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc., a metabolic therapeutics company, has announced advancements in its Rejuva Smart GLP-1 pancreatic gene therapy platform, specifically with its clinical candidate RJVA-001 targeting type 2 diabetes . The company revealed new preclinical data at the American Diabetes Association's 85th Scientific Sessions, demonstrating that a single dose of Rejuva was well-tolerated in healthy mice and effectively prevented obesity and diabetes in models exposed to a high-fat diet. These findings support the progression of RJVA-001 toward first-in-human studies, with preliminary clinical data expected in 2026, pending regulatory authorization. The study results have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL2zLmJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","GUTS","NDAQ","LU2095319765.USD","BK4082","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2544974884","title":"Fractyl Health Announces New Patents for Gut Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2544974884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544974884?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:32","pubTimestamp":1750246331,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Fractyl Health, Inc. ( ($GUTS) ). On June 18, 2025, Fractyl Health, Inc. announced the issuance of two new U.S....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fractyl-health-announces-new-patents-for-gut-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fractyl-health-announces-new-patents-for-gut-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2544979171","title":"Fractyl Health Expands Intellectual Property Portfolio with Two New U.S. Patents for Metabolic Disease Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2544979171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544979171?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:00","pubTimestamp":1750244426,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc. has announced the issuance of two new U.S. patents, further reinforcing its leadership in duodenal resurfacing applications. The patents, U.S. Patent No. 12,329,439 and U.S. Patent No. 12,303,185, focus on electrical energy ablation systems for treating tissue, particularly targeting the duodenal mucosa with various energy forms, including thermal and non-thermal electrical energy. These additions to Fractyl's intellectual property portfolio are designed to protect core innovations in metabolic disease treatment and reflect the company's ongoing commitment to advancing gut-targeted therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDLc9lBLm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NDAQ","BK4112","LU2210149790.SGD","BK4588","LU2095319765.USD","BK4585","BK4082","IE00B64PRP62.GBP","IE00BKPKM429.USD","GUTS","LU2210150020.SGD"],"gpt_icon":0},{"id":"2543568644","title":"Fractyl Health Inc. Unveils Promising Preclinical Data on GLP-1-Based Gene Therapy for Obesity and Diabetes Prevention at ADA Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2543568644","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543568644?lang=en_us&edition=fundamental","pubTime":"2025-06-13 19:00","pubTimestamp":1749812417,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc. Unveils Promising Preclinical Data on GLP-1-Based Gene Therapy for Obesity and Diabetes Prevention at ADA Scientific Sessions. Fractyl Health Inc., a company specializing in metabolic therapeutics, has announced that it will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform. The presentation is scheduled to take place at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois, from June 20-23, 2025. The data will be shared in a poster session titled \"Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat-Fed Mice.\" The presentation is set for June 22, 2025, from 12:30 p.m. to 1:30 p.m. The poster will be available on the Fractyl website following the session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL7vL31x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BKPKM429.USD","BK4588","NDAQ","IE00BGHQF748.EUR","BK4112","BK4585","GUTS","LU2210149790.SGD","LU2095319765.USD","BK4082","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2543542254","title":"Fractyl Health Inc. Conducted Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2543542254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543542254?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:19","pubTimestamp":1749759570,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc. held its Annual Meeting of Stockholders on June 11, 2025. The meeting included the election of Class I directors, resulting in the election of William W. Bradley, Ajay Royan, and Amy W. Schulman. Additionally, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2025, and is solely responsible for the information ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL19Jhkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2540068895","title":"BRIEF-Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2540068895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540068895?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:13","pubTimestamp":1749035627,"startTime":"0","endTime":"0","summary":"BRIEF-Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers NationwideJune 4 (Reuters) - Fractyl Health Inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"gpt_icon":0},{"id":"2540706859","title":"Fractyl Health, Bariendo sign non-binding LOI, to offer Revita nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2540706859","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540706859?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:10","pubTimestamp":1749035437,"startTime":"0","endTime":"0","summary":"Fractyl Health (GUTS) and Bariendo announced the signing of a non-binding Letter of Intent, LOI, to explore a future collaboration centered on Frac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fractyl-health-bariendo-sign-non-binding-loi-to-offer-revita-nationwide-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fractyl-health-bariendo-sign-non-binding-loi-to-offer-revita-nationwide-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2540450050","title":"Fractyl Health Inc - Expects Key Data Readouts for Revita in 2025 and 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2540450050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540450050?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:02","pubTimestamp":1749034963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2540050172","title":"Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across Its Bariatric and Metabolic Endoscopy Centers Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050172?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:02","pubTimestamp":1749034963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S707D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","GUTS"],"gpt_icon":0},{"id":"2540050192","title":"Fractyl Health and Bariendo Join Forces to Potentially Offer Revita Nationwide for Post-GLP-1 Weight Maintenance","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050192","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050192?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:00","pubTimestamp":1749034840,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc., a leading metabolic therapeutics company, has announced a partnership with Bariendo Inc., an innovative obesity care platform. The two companies have signed a non-binding Letter of Intent to explore a collaboration centered on Fractyl's investigational procedure, Revita, as a sustainable solution for post-GLP-1 weight maintenance. This partnership aims to address the increasing demand for endoscopic alternatives that offer a holistic approach to maintaining weight loss after GLP-1 drug discontinuation. The collaboration will focus on preparing for the potential integration of Revita into Bariendo's clinical offerings, pending FDA approval, and will include initiatives such as clinical workflow design and provider education.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL1TLtPk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4082","IE00B64PRP62.GBP","LU2210149790.SGD","BK4588","LU2095319765.USD","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","GUTS","BK4585","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2540050930","title":"Innovative Weight Management Solution Drives Buy Rating for Fractyl Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050930?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:55","pubTimestamp":1749034548,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Whitney Ijem reiterated a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) today and set a price target of $12...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innovative-weight-management-solution-drives-buy-rating-for-fractyl-health-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innovative-weight-management-solution-drives-buy-rating-for-fractyl-health-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GUTS"],"gpt_icon":0},{"id":"2536897616","title":"Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2536897616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536897616?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:07","pubTimestamp":1747656422,"startTime":"0","endTime":"0","summary":"Fractyl Health  said Monday that it has submitted the first module of its clinical trial application in Europe for RJVA-001, a gene therapy candidate from its Rejuva platform targeting type 2 diabetes.The metabolic therapeutics company said it expects to begin first-in-human dosing and share preliminary data next year, pending regulatory approval.The upcoming phase 1/2 trial will assess safety, tolerability, and early efficacy in adults with poorly controlled type 2 diabetes, even while taking multiple glucose-lowering medications, including GLP-1 receptor agonists, the company said.The study will consist of a dose-escalation phase followed by a potential expansion cohort, with participants receiving the gene therapy via endoscopic ultrasound-guided injection and being monitored for up to 12 months, as well as a five-year long-term follow-up, the company said.Shares of the company rose nearly 3% in recent premarket activity on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GUTS","BK4156","BK4082"],"gpt_icon":0},{"id":"2536683047","title":"Fractyl Health Inc. Submits First Clinical Trial Application Module in Europe for RJVA-001 Gene Therapy in Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2536683047","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536683047?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:00","pubTimestamp":1747652415,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass., May 19, 2025  -- Fractyl Health, Inc. , a company specializing in metabolic therapeutics, has announced the submission of the first module of its Clinical Trial Application  in Europe for RJVA-001. This gene therapy candidate from Fractyl's Rejuva platform aims to address type 2 diabetes and obesity by expressing glucagon-like peptide-1  locally in pancreatic beta cells. The therapy is designed to enable physiologic hormone secretion without the high circulating levels associated with current systemic GLP-1 drug therapies, potentially reducing side effects. Pending regulatory clearance, Fractyl plans to begin first-in-human dosing and report preliminary data in 2026. The study will assess the safety, tolerability, and early efficacy of this one-time, pancreas-targeted gene therapy in patients with inadequately controlled type 2 diabetes and obesity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL4q6hJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","BK4588","IE00B64PRP62.GBP","BK4082"],"gpt_icon":0},{"id":"2536683228","title":"Fractyl Health Advances Rejuva® Gene Therapy Platform With Submission of First Clinical Trial Application Module in Europe for Rjva-001 in Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2536683228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536683228?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:00","pubTimestamp":1747652400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUA5X4DFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","GUTS"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":64,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GUTS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"GUTS","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2024-11-12","symbol":"GUTS","fiscalQuarterEnding":"2024/09","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-05-13","symbol":"GUTS","fiscalQuarterEnding":"2024/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":-0.75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GUTS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GUTS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1744776000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GUTS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GUTS","date":"2025-06-20","current":-1.049809,"percent":0.846626,"low":-8.89576,"twenty":-4.300028,"median":-1.995599,"eighty":-1.109173,"high":-0.674617,"avg":-2.60624,"sd":1.710369,"marketCap":93545374},"quantilePoints":[{"date":"2024-02-09","current":-7.199681,"twenty":-7.926572,"median":-7.255064,"eighty":-7.199681,"marketCap":495114890},{"date":"2024-02-16","current":-5.558985,"twenty":-7.340906,"median":-7.07161,"eighty":-5.493911,"marketCap":382285824},{"date":"2024-02-23","current":-5.7459,"twenty":-7.221834,"median":-5.84628,"eighty":-5.558985,"marketCap":395139768},{"date":"2024-03-01","current":-6.230494,"twenty":-7.199681,"median":-5.94666,"eighty":-5.558985,"marketCap":428464809},{"date":"2024-03-08","current":-6.299721,"twenty":-7.091686,"median":-6.265108,"eighty":-5.600521,"marketCap":433225529},{"date":"2024-03-15","current":-4.67287,"twenty":-6.990614,"median":-5.94666,"eighty":-5.398377,"marketCap":321348606},{"date":"2024-03-22","current":-5.039777,"twenty":-6.954615,"median":-5.756284,"eighty":-4.992702,"marketCap":346580423},{"date":"2024-03-28","current":-4.984395,"twenty":-6.796776,"median":-5.655904,"eighty":-5.006548,"marketCap":342771847},{"date":"2024-04-05","current":-4.645542,"twenty":-6.52125,"median":-5.558985,"eighty":-4.724099,"marketCap":358129452},{"date":"2024-04-12","current":-4.260483,"twenty":-6.388333,"median":-5.351301,"eighty":-4.623184,"marketCap":328444925},{"date":"2024-04-19","current":-4.080375,"twenty":-6.308029,"median":-5.233615,"eighty":-4.529956,"marketCap":314560227},{"date":"2024-04-26","current":-4.173535,"twenty":-6.27203,"median":-5.126311,"eighty":-4.286983,"marketCap":321741967},{"date":"2024-05-03","current":-4.043112,"twenty":-6.230494,"median":-4.984395,"eighty":-4.190924,"marketCap":311687531},{"date":"2024-05-10","current":-3.863004,"twenty":-6.11696,"median":-4.746967,"eighty":-4.142482,"marketCap":297802833},{"date":"2024-05-17","current":-4.677292,"twenty":-5.874663,"median":-4.707484,"eighty":-4.142482,"marketCap":320305619},{"date":"2024-05-24","current":-5.285549,"twenty":-5.766668,"median":-4.811037,"eighty":-4.161114,"marketCap":361959713},{"date":"2024-05-31","current":-4.700095,"twenty":-5.762514,"median":-4.746967,"eighty":-4.163598,"marketCap":321867221},{"date":"2024-06-07","current":-4.52524,"twenty":-5.733439,"median":-4.74206,"eighty":-4.176019,"marketCap":309892994},{"date":"2024-06-14","current":-4.14056,"twenty":-5.683595,"median":-4.714084,"eighty":-4.173535,"marketCap":283549695},{"date":"2024-06-21","current":-3.748885,"twenty":-5.639289,"median":-4.700095,"eighty":-4.13846,"marketCap":256727426},{"date":"2024-06-28","current":-3.098426,"twenty":-5.614367,"median":-4.679113,"eighty":-4.13216,"marketCap":212183302},{"date":"2024-07-05","current":-3.126403,"twenty":-5.558985,"median":-4.67287,"eighty":-4.067954,"marketCap":214099178},{"date":"2024-07-12","current":-3.273281,"twenty":-5.558985,"median":-4.618315,"eighty":-4.043112,"marketCap":224157529},{"date":"2024-07-15","current":-3.203339,"twenty":-5.545139,"median":-4.608278,"eighty":-4.043112,"marketCap":219367838},{"date":"2024-08-02","current":-1.909414,"twenty":-5.531294,"median":-4.604496,"eighty":-3.987217,"marketCap":130758558},{"date":"2024-08-09","current":-1.272942,"twenty":-5.44822,"median":-4.571014,"eighty":-3.880394,"marketCap":87172372},{"date":"2024-08-16","current":-2.030155,"twenty":-5.362548,"median":-4.535732,"eighty":-3.763178,"marketCap":112628952},{"date":"2024-08-23","current":-2.513937,"twenty":-5.323174,"median":-4.395959,"eighty":-3.157177,"marketCap":139468192},{"date":"2024-08-30","current":-3.092747,"twenty":-5.304232,"median":-4.330871,"eighty":-3.111015,"marketCap":171579426},{"date":"2024-09-06","current":-2.833578,"twenty":-5.2807,"median":-4.287438,"eighty":-3.037457,"marketCap":157201261},{"date":"2024-09-13","current":-2.470742,"twenty":-5.255768,"median":-4.264795,"eighty":-3.016296,"marketCap":137071832},{"date":"2024-09-20","current":-2.349797,"twenty":-5.230425,"median":-4.220114,"eighty":-2.883684,"marketCap":130362022},{"date":"2024-09-27","current":-2.185656,"twenty":-5.202856,"median":-4.173535,"eighty":-2.641793,"marketCap":121255851},{"date":"2024-10-04","current":-1.995599,"twenty":-5.14085,"median":-4.150837,"eighty":-2.522576,"marketCap":110711864},{"date":"2024-10-11","current":-2.038794,"twenty":-5.128388,"median":-4.12385,"eighty":-2.410269,"marketCap":113108225},{"date":"2024-10-18","current":-2.151101,"twenty":-5.116238,"median":-4.067954,"eighty":-2.30833,"marketCap":119338762},{"date":"2024-10-25","current":-2.168379,"twenty":-5.079786,"median":-4.043112,"eighty":-2.220212,"marketCap":120297307},{"date":"2024-10-31","current":-2.894051,"twenty":-5.039777,"median":-4.043112,"eighty":-2.211573,"marketCap":160556166},{"date":"2024-11-08","current":-2.081989,"twenty":-4.998899,"median":-3.941127,"eighty":-2.185656,"marketCap":115504585},{"date":"2024-11-15","current":-1.598099,"twenty":-4.984395,"median":-3.863004,"eighty":-2.15542,"marketCap":100526792},{"date":"2024-11-22","current":-1.575159,"twenty":-4.935976,"median":-3.777242,"eighty":-2.133823,"marketCap":99083824},{"date":"2024-11-29","current":-1.95748,"twenty":-4.924867,"median":-3.755879,"eighty":-2.090628,"marketCap":123133296},{"date":"2024-12-06","current":-1.636331,"twenty":-4.88286,"median":-3.203339,"eighty":-2.064711,"marketCap":102931740},{"date":"2024-12-13","current":-1.686032,"twenty":-4.835403,"median":-3.126403,"eighty":-2.038794,"marketCap":106058171},{"date":"2024-12-20","current":-1.391646,"twenty":-4.764415,"median":-3.10542,"eighty":-1.995599,"marketCap":87540078},{"date":"2024-12-27","current":-1.575159,"twenty":-4.746556,"median":-3.092747,"eighty":-1.97958,"marketCap":99083824},{"date":"2025-01-03","current":-1.628684,"twenty":-4.743771,"median":-3.023635,"eighty":-1.95748,"marketCap":102450750},{"date":"2025-01-10","current":-1.452817,"twenty":-4.739262,"median":-3.02149,"eighty":-1.912585,"marketCap":91387993},{"date":"2025-01-17","current":-1.383999,"twenty":-4.725274,"median":-2.961882,"eighty":-1.793847,"marketCap":87059088},{"date":"2025-01-24","current":-1.567513,"twenty":-4.714084,"median":-2.915648,"eighty":-1.74338,"marketCap":98602835},{"date":"2025-01-31","current":-1.483403,"twenty":-4.707484,"median":-2.876773,"eighty":-1.674563,"marketCap":93311951},{"date":"2025-02-07","current":-1.231071,"twenty":-4.700095,"median":-2.751508,"eighty":-1.628684,"marketCap":77439299},{"date":"2025-02-14","current":-1.269303,"twenty":-4.679113,"median":-2.600327,"eighty":-1.598099,"marketCap":79844247},{"date":"2025-02-21","current":-1.116375,"twenty":-4.677656,"median":-2.557132,"eighty":-1.575159,"marketCap":70224458},{"date":"2025-02-28","current":-1.116375,"twenty":-4.673754,"median":-2.479381,"eighty":-1.574866,"marketCap":70224458},{"date":"2025-03-07","current":-1.118071,"twenty":-4.651008,"median":-2.410269,"eighty":-1.558338,"marketCap":76804746},{"date":"2025-03-14","current":-0.858137,"twenty":-4.63179,"median":-2.367075,"eighty":-1.536928,"marketCap":58948866},{"date":"2025-03-21","current":-0.875941,"twenty":-4.612293,"median":-2.315241,"eighty":-1.500225,"marketCap":60171871},{"date":"2025-03-28","current":-0.897305,"twenty":-4.602227,"median":-2.276365,"eighty":-1.465051,"marketCap":61639478},{"date":"2025-04-04","current":-0.811847,"twenty":-4.596288,"median":-2.211573,"eighty":-1.424369,"marketCap":55769051},{"date":"2025-04-11","current":-0.674617,"twenty":-4.575848,"median":-2.189976,"eighty":-1.390881,"marketCap":46342125},{"date":"2025-04-17","current":-0.790483,"twenty":-4.567288,"median":-2.177017,"eighty":-1.373294,"marketCap":54301445},{"date":"2025-04-25","current":-0.911548,"twenty":-4.553655,"median":-2.15542,"eighty":-1.28911,"marketCap":62617882},{"date":"2025-05-02","current":-0.904427,"twenty":-4.533633,"median":-2.142462,"eighty":-1.239408,"marketCap":62128680},{"date":"2025-05-09","current":-1.176397,"twenty":-4.51413,"median":-2.125184,"eighty":-1.175327,"marketCap":80811449},{"date":"2025-05-16","current":-0.906903,"twenty":-4.440265,"median":-2.090628,"eighty":-1.159286,"marketCap":80811449},{"date":"2025-05-23","current":-0.964616,"twenty":-4.366843,"median":-2.07335,"eighty":-1.14827,"marketCap":85953996},{"date":"2025-05-30","current":-1.044313,"twenty":-4.342464,"median":-2.064711,"eighty":-1.127782,"marketCap":93055608},{"date":"2025-06-06","current":-1.066299,"twenty":-4.331699,"median":-2.043114,"eighty":-1.113119,"marketCap":95014673},{"date":"2025-06-13","current":-1.192715,"twenty":-4.319408,"median":-2.030155,"eighty":-1.113119,"marketCap":106279300},{"date":"2025-06-20","current":-1.049809,"twenty":-4.300028,"median":-1.995599,"eighty":-1.109173,"marketCap":93545374}],"updateTime":1750678967276}}}